


IAP45-00000000000000000000000000000000 IAP45-00000000000000000000000000000000 04 JAN 2006 T



PATENT  
Customer No. 22,852  
Attorney Docket No. 06267.0127

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Jukka GYNTHER et al.

) Group Art Unit: To Be Assigned

Application No.: 10/541,387

) Examiner: To Be Assigned

Filed: July 1, 2005

) Confirmation No.: To Be Assigned

For: COMPOUNDS HAVING PROLYL  
OLIGOPEPTIDASE INHIBITORY  
ACTIVITY

)

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed foreign and non-patent literature documents are attached.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do

not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.


Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: January 4, 2006

By: 

Steven J. Scott  
Reg. No. 43,911

**Complete if Known**

Sheet	1	of	2	Application Number	10/541,387
				Filing Date	July 1, 2005
				First Named Inventor	Jukka GYNTHER
				Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	06267.0127

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS**

Examiner Initials	Cite No. <sup>1</sup>	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

**Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.****FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				


**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation
		Sherwin Wilk, "Minireview Prolyl Endopeptidase," Life Sciences, Vol. 33, pp. 2149-2157, 1983	
		Rhonda O'Leary et al., "Thyrotropin-Releasing Hormone," Journal of Neurochemistry, Vol. 65, No. 3, pp. 953-963, 1995	
		Tadashi Yoshimoto et al., "Specific Inhibitors for Prolyl Endopeptidase and Their Anti-Amnestic Effect," J. Pharmacobio-Dyn., Vol. 10, pp. 730-735, 1987	
		Neil W. Kowall et al., "An <i>in vivo</i> model for the neurodegenerative effects of $\beta$ amyloid and protection by substance P," Proc. Natl. Acad. Sci., Vol. 88, pp. 7247-7251, 1991	
		Daniel Nöteberg et al., "New Proline Mimetics: Synthesis of Thrombin Inhibitors Incorporating Cyclopentane- and Cyclopentenedicarboxylic Acid Templates in the P2 Position. Binding Conformation Investigated by X-ray Crystallography," J. Med. Chem., Vol. 43, pp. 1705-1713, 2000	
		Eric Beausoleil et al., "5- <i>tert</i> -Butylproline," J. Org. Chem., Vol. 61, pp. 9447-9454, 1996	
		Iván Collado et al., "Stereoselective Addition of Grignard-Derived Organocopper Reagents to <i>N</i> -Acyliminium Ions: Synthesis of Enantiopure 5- and 4,5-substituted Prolinates," J. Org. Chem., Vol. 60, pp. 5011-5015, 1995	
		Herman Gershon et al., "Amino Acid Analogs. I. Analogs of the Glutamic Acid, Proline Interconversion. Part I. $\omega$ -Methyl- and $\omega$ -Phenylketoglutamic Acids and 5-Methyl- and 5-Phenylprolines," Amino Acid Analogs. I, Vol. 26, pp. 2347-2350, 1961	
		Teresa L. Ho et al., "An Asymmetric Synthesis of <i>cis</i> -5-Alkylproline Derivatives," Vol. 51, No. 13, pp. 2405-2408, 1986	
		Houda H. Ibrahim et al., "Synthesis of Enantiopure $\alpha$ -Oxo $\alpha$ -Amino Esters and Prolines via Acylation of <i>N</i> -(Phenylfluorenyl)glutamate Enolates," J. Org. Chem., Vol. 58, pp. 6438-6441, 1993	
		C. G. Overberger et al., "Synthesis and Resolution of <i>cis</i> - and <i>trans</i> -5-Methylproline," Macromolecules, Vol. 5, No. 4, pp. 368-372, 1972	
		Stephen G. Pyne et al., "Asymmetric Synthesis of Proline Derivatives from (2R) and (2S)-2- <i>tert</i> -Butyl-3-Benzoyl-4-Methyleneoxazolidin-5-one," Tetrahedron, Vol. 51, pp. 5157-5169, 1995	
		Yasushi Sanno, "Studies on the Active Compounds of <i>Digenea simplex</i> Ag. and Related Compounds. LXII. Syntheses of Proline Derivatives by the Cyclization of $\alpha$ -Aminoketones," Yakugaku Zasshi, Vol. 79, No. 10, pp. 1113-1123, 1958	

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.**



## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

---

2

Complete if Known	
Application Number	10/541,387
Filing Date	July 1, 2005
First Named Inventor	Jukka GYNTHER
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	06267.0127

## **NON PATENT LITERATURE DOCUMENTS**

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.